---
id: 060
title: Fosfomycin for Uncomplicated Cystitis
category: antimicrobials
subcategory: fosfomycin
tags: [fosfomycin, UTI, cystitis, ESBL, single-dose, first-line]
difficulty: medium
---

## Question

What is fosfomycin's mechanism of action and why is it a **first-line agent** for uncomplicated cystitis? Use the **"SINGLE-DOSE Wins"** mnemonic.

## Answer

### **"SINGLE-DOSE Wins" Mnemonic:**

**SINGLE:**
- **S**ingle 3g dose (one-time treatment)
- **I**nhibits MurA enzyme (cell wall synthesis)
- **N**o resistance to ESBL producers
- **G**ood for fluoroquinolone-resistant *E. coli*
- **L**ow toxicity, excellent safety
- **E**xcellent compliance (one dose)

**DOSE Wins:**
- **D**irect IDSA first-line recommendation
- **O**ral bioavailability 40% (adequate for cystitis)
- **S**afer than nitrofurantoin in pregnancy (Category B)
- **E**SBL *E. coli* susceptibility retained

### **Mechanism of Action:**

**Target:** **MurA enzyme** (UDP-N-acetylglucosamine enolpyruvyl transferase)
- **First committed step** of peptidoglycan synthesis
- Covalent binding to cysteine in active site
- Blocks bacterial cell wall formation
- **Bactericidal** effect
- **Unique mechanism** → no cross-resistance with other classes

### **Spectrum of Activity:**

| Organism | Activity | Notes |
|----------|----------|-------|
| ***E. coli*** | Excellent | Including ESBL, FQ-resistant |
| ***Enterococcus faecalis*** | Good | VRE susceptible |
| ***K. pneumoniae*** | Variable | **Avoid** (fosA genes common) |
| **Other Enterobacterales** | Variable | *Citrobacter*, *Enterobacter*, *Serratia* |
| ***S. saprophyticus*** | Good | Common in young women |
| ***P. aeruginosa*** | Poor | Generally resistant |
| ***Proteus mirabilis*** | Variable | Often resistant |

**Key Point:** **Do NOT use for *K. pneumoniae*** (carries fosA hydrolase genes → intrinsic resistance)

## Key Points

### **FDA-Approved Indication:**
- **Uncomplicated UTI (acute cystitis) in women**
- Caused by susceptible *E. coli* or *E. faecalis*

### **IDSA Guideline Recommendation (2024):**

**First-Line Agents for Uncomplicated Cystitis:**
1. Nitrofurantoin 100 mg BID × 5 days
2. TMP-SMX DS BID × 3 days (if local resistance <20%)
3. **Fosfomycin 3g × 1 dose** (single-dose option)

**Advantages of Fosfomycin:**
- **Single dose** (best compliance)
- Active against **ESBL *E. coli***
- Active against **FQ-resistant *E. coli***
- **Low resistance rates** (<5% in most regions)
- Minimal impact on gut microbiome
- Safe in pregnancy (Category B)

### **Dosing:**

**Uncomplicated Cystitis:**
- **Fosfomycin tromethamine 3g packet PO × 1 dose**
- Mix with 3-4 oz water
- Take on **empty stomach** (2 hours before/after meals)
- Best if taken **at bedtime** after voiding

**Complicated UTI/Pyelonephritis:**
- **NOT recommended** by IDSA (oral bioavailability too low for systemic infections)
- If used off-label: 3g PO q48-72h × 2-3 weeks
- Controversial efficacy

### **Pharmacokinetics:**

| Parameter | Value | Clinical Implication |
|-----------|-------|---------------------|
| **Bioavailability (PO)** | 37-41% | Low serum levels, high urine levels |
| **Urine concentration** | Very high (>1000 µg/mL) | Excellent for cystitis |
| **Serum levels** | Low | **Not adequate for pyelonephritis** |
| **Half-life** | 5.7 hours | Prolonged urinary excretion |
| **Urine excretion** | >90% unchanged | Ideal for UTI |
| **Tissue penetration** | Poor | Bladder only |

### **Why Single Dose Works:**

1. **Very high urinary concentrations** (>1000 µg/mL for 24-48 hours)
2. **Bactericidal** against uropathogens
3. **Prolonged urinary excretion** (effective for 24-36 hours)
4. MIC90 for *E. coli*: 4-32 µg/mL (easily exceeded in urine)

### **Clinical Pearls:**
- **Best compliance** of any UTI antibiotic (one dose)
- Preferred for **ESBL *E. coli* cystitis** (IDSA 2024 guidance)
- **Safe in pregnancy** (Category B) - alternative to nitrofurantoin near term
- **Minimal collateral damage** (low resistance selection)
- **DO NOT use** for:
  - Pyelonephritis (inadequate serum levels)
  - Complicated UTI (poor systemic levels)
  - *K. pneumoniae* infections (fosA resistance)
  - *Pseudomonas* infections (resistant)

### **When Fosfomycin Fails:**
- **Pyelonephritis** (inadequate kidney tissue levels)
- **Systemic infections** (low bioavailability)
- ***K. pneumoniae*** UTI (fosA genes)
- **Recurrent UTI** (may need longer therapy)

## Sources

- [PMC12240282: Single-Dose Fosfomycin Efficacy and Safety Meta-Analysis 2024]
- [PMC4904571: Fosfomycin First-Line for Acute Uncomplicated Cystitis]
- [IDSA 2024: AMR Guidance for Gram-Negative Infections]
- [PMC5287057: Fosfomycin Mechanism and Resistance]

## Media

N/A
